Cell Marque Antibodies

69 Pages·2013·10.99 MB·English

Supplement zum
Cell Marque Katalog
Vol.10
Stand Januar 2016
Informationen aus erster Hand
www.medac-diagnostika.de
REA_D80_SuppVol10-01/2016che
Adenovirus infection is associated with a broad spectrum of clinical disease in both children and adults. It has gained more
attention as an important complication in patients who have undergone bone marrow or solid organ transplantation. Reactivity Paraffin
The incidence of adenovirus infection in bone marrow transplant patients has been reported at 5-20%. Adenovirus infection
on morphology should be differentially diagnosed from other virus infections, especially CMV infection. Anti-adenovirus can Visualization Cytoplasmic,
assist in this differential diagnosis by showing a round or crescent-shaped nuclear inclusion, generally within the surface Nuclear
epithelium and is exclusively intra-nuclear in location.
Control Adenovirus Infected Tissue
Stability Up to 36 mo. at 2-8°C
Isotype IgG/k
1
Protocols
• Pretreatment: Protease
• Incubation Time:
HiDef Detection™ 10-30 min. RT
or ultraView™ 16-32 min. at 37° C
Please refer to product insert for complete protocol.
References
1. Ison, MG. Clin Infect Dis. 2006; 43:
331–9.
2. Shayan K, et al. Arch Pathol Lab Med
†Analyte Specific Reagent: Analytical and performance characteristics are not established. 2003;127:1615-8.
For IVD product, please remove the “ASR” suffix from the end of the catalog number when ordering.
For RUO product, please replace the “ASR” suffix with an “RUO” suffix at the end of the catalog number when ordering.
Mouse Monoclonal
ASR†
Clone: 20/11 & 2/6
0.1 ml, concentrate ...............212M-14 (ASR) IVD 1 800.665.7284 (N. America)
0.5 ml, concentrate ...............212M-15 (ASR) +1 916.746.8900 (direct)
1 ml, concentrate ................212M-16 (ASR) IVD +1 916.746.8989 (fax)
1 ml, prediluted ..................212M-17 (ASR) [email protected]
7 ml, prediluted ..................212M-18 (ASR) www.cellmarque.com
RUO
Positive control slides ............212S
* ultraView is a trademark of Roche.
Cell Marque New Product
Sebaceous carcinoma is a relatively uncommon cutaneous malignancy and mimics other malignant neoplasms, such as basal
and squamous cell carcinomas, and benign processes, such as chalazions and blepharitis, sometimes resulting in delayed Reactivity Paraffin
diagnosis and suboptimal treatment. Adipophilin is present in milk fat globule membranes and on the surface of lipid droplets
in various normal cell types. Recently, it has been reported that adipophilin was expressed in 16 of 16 (100%) sebaceous Visualization Membranous
adenomas with a specific pattern: membranous with strong uptake at the periphery of intracytoplasmic lipid vacuoles. Of
25 sebaceous carcinomas, 23 (92%) were also labeled with a similar pattern. Additionally, in cases of poorly differentiated Control Sebaceous Neoplasms
sebaceous carcinoma (n=11), in which sebaceous differentiation could not have been reliably interpreted in H&E sections, (intracytoplasmic lipid
adipophilin highlighted the sebocytes with a strong membranous labeling of intracytoplasmic lipid droplets in 9 of 11 cases droplet)
(82%). Moreover, 10 of 10 (100%) xanthelasmas, 9 of 10 (90%) xanthogranulomas, 6 of 6 (100%) xanthomas, and 9 of 13 (63%) Stability Up to 36 mo. at 2-8°C
metastatic renal cell carcinomas were also weakly to moderately positive for adipophilin. Expression of adipophilin with a
membranous pattern of staining was not seen in any of the other clear cell lesions of the skin, including basal and squamous Protocols
cell carcinomas, trichilemmomas, clear cell hidradenomas, or balloon cell nevi. Interestingly, a nonspecific granular uptake
• Pretreatment: EDTA/Trilogy
of antibody was seen in adjacent macrophages, keratohyalin granules of epithelial squamous cells, and some tumor cells.
• Incubation Time:
Therefore, adipophilin is an antibody used on formalin-fixed paraffin-embedded tissue and helpful in the identification of
HiDef Detection™ 10-30 min. RT
intracytoplasmic lipids, as seen in sebaceous lesions. It is especially helpful in identifying intracytoplasmic lipid vesicles in
or ultraView™ 16-32 min. at 37° C
poorly differentiated sebaceous carcinomas in challenging cases such as small periocular biopsy specimens.
Please refer to product insert for complete protocol.
Lesions
Adipophilin CK Cocktail CK 5 & 14 EMA Ber-EP4
Sebaceous Adenoma + + + + +
Sebaceous Carcinoma + + + + + References
Basal Cell Carcinoma - + - - +
Squamous Cell Carcinoma - + + + - 1. Lai TF, et al. DermatolSurg 2004;
30:222.
2. Ostler DA, et al. Mod Pathol 2010;
23:567.
Rabbit Polyclonal
IVD
0.1 ml, concentrate .....................393A-14 IVD 1 800.665.7284 (N. America)
0.5 ml, concentrate .....................393A-15 +1 916.746.8900 (direct)
1 ml, concentrate ......................393A-16 IVD +1 916.746.8989 (fax)
1 ml, prediluted ........................393A-17 [email protected]
7 ml, prediluted ........................393A-18 www.cellmarque.com
RUO
Positive control slides ..................393S
* ultraView is a trademark of Roche.
Cell Marque New Product
ALDH1A1 belongs to the ALDH enzymes, a family of evolutionarily conserved enzymes comprised of 19 isoforms that are
localized in the cytoplasm, mitochondria or nucleus. ALDH1A1 is predominantly expressed in the epithelium of testis, brain, Reactivity Paraffin
eye, liver, kidney, as well as neural and hematopoietic stem cells. Recently, it has been reported that high ALDH1A1 mRNA
expression was seen in solitary fibrous tumor (SFT) and hemangiopericytoma (HPC), compared to meningiomas and synovial Visualization Cytoplasmic
sarcomas. An immunohistochemical study with ALDH1A1 antibody in 243 meningeal tumors (tissue microarray), including
25 central nervous system SFTs, 13 extrameningeal SFTs, 55 central nervous system HPCs, 163 meningiomas, and 98 synovial Control Solitary Fibrous Tumor
sarcomas found that 21 of 25 meningeal SFTs (84%), 11 of 13 extrameningeal SFTs (84.6%), and 18 of 24 (85.4%) meningeal Stability Up to 36 mo. at 2-8°C
HPCs were positive with anti-ALDH1A1 antibody. Anti-ALDH1A1 can be combined with anti-CD34 to aid in the differentiation
between SFT, HPC, meningioma, and synovial sarcoma. 24/25 (96%) meningeal SFTs and 54/55 (98%) meningeal HPCs were Isotype IgG
positive for ALDH1A1 and/or CD34 whereas only 10/163 (6%) meningiomas and 7/98 (7%) synovial sarcomas were positive 1
for ALDH1A1 and/or CD34. Anti-ALDH1A1 IHC has been recommended for routine use in association with anti-CD34 for the Protocols
differentiation among SFT, HPC, meningioma, and synovial sarcoma.
• Pretreatment: EDTA/Trilogy
• Incubation Time:
Neoplasm HiDef Detection™ 10-30 min. RT
ALDH1A1 EMA CD34 CK 8 & 18 CK 19
or ultraView™ 16-32 min. at 37° C
Solitary Fibrous Tumor + - + - -
Please refer to product insert for complete protocol.
Hemangiopericytoma + - + - -
Meningioma - + -/+ - -
Synovial Sarcoma - + - + +
References
1. Marcato P, et al. Cell Cycle 2011;
10:1378–1384.
2. Chute JP, et al. Proc Natl Acad Sci
USA 2006, 103(31):11707–11712.
3. Bouvier C, et al. Acta
Neuropathologica Communications
2013, 1:10
Mouse Monoclonal
IVD
Clone: 44
0.1 ml, concentrate .....................400M-14 IVD 1 800.665.7284 (N. America)
0.5 ml, concentrate .....................400M-15 +1 916.746.8900 (direct)
1 ml, concentrate ......................400M-16 IVD +1 916.746.8989 (fax)
1 ml, prediluted ........................400M-17 [email protected]
7 ml, prediluted ........................400M-18 www.cellmarque.com
RUO
Positive control slides ..................400S
* ultraView is a trademark of Roche.
Cell Marque New Product
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver accounting for an estimated
70%-85% of total liver cancers worldwide. Diagnostic pitfalls exist in the morphologic distinction of HCC from other Reactivity Paraffin
hepatocellular and non-hepatocellular mass lesions. In difficult or equivocal cases, the application of immunohistochemical
(IHC) panels has been shown to aid in the distinction of benign and malignant liver lesions. In particular, the application of Visualization Cytoplasmic,
CD10, polyclonal carcinoembryonic antigen, alpha-fetoprotein, HepPar-1, and glypican-3 (GPC-3) IHC has proven valuable in Nuclear
liver biopsy and FNA cytology specimens. Recent studies have shown the usefulness of anti-Arginase-1 as an IHC marker of
hepatocellular differentiation in benign and malignant lesions of liver on biopsy as well as fine needle aspiration specimens. Control Normal Liver,
Hepatocellular Carcinoma
In summary, anti-Arginase-1 is useful in distinguishing between HCC and an adenocarcinoma although it is not useful in Stability Up to 36 mo . at 2-8°C
distinguishing between hepatic adenoma and well-differentiated HCC.
Isotype IgG
Liver Neoplasms
Arginase-1 Hep Par-1 Glypican-3 CD10 pCEA Protocols
Hepatic Adenoma + + - + +
• Pretreatment: EDTA/Trilogy™
Hepatocellular Carcinoma + + + + +
• Incubation Time:
Metastatic Adenocarcinoma - - - -/+ -/+
HiDef Detection™ 10-30 min . RT
or ultraView™ 16-32 min . at 37° C
Please refer to product insert for complete protocol.
References
1 . Yan BC, et al . J Surg Pathol .
2010;34:1147-1154 .
2 . McKnight, R . et al . Cancer
Cytopathology . 2012, published
Top: Arginase-1 stains hepatocellular carcinoma in nuclear and cytoplasmic pattern while endothelial cells are negative. on- line . DOI: 10 .1002/cncy .21184
Right lower corner: Arginase-1 is strongly and diffusely positive for hepatocellular carcinoma.
Rabbit Monoclonal Rabbit Monoclonal
IVD
Clone: SP156 Clone: SP156
0 .1 ml, concentrate . . . . . . . .380R-14 Ventana® 50 Test Dispenser IVD 1 800.665.7284 (N. America)
0 .5 ml, concentrate . . . . . . . .380R-15 760-4801 +1 916.746.8900 (direct)
1 ml, concentrate . . . . . . . . .380R-16 IVD +1 916.746.8989 (fax)
Dispenser orders:
1 ml, prediluted . . . . . . . . . . .380R-17 [email protected]
1 800 .227 .2155
7 ml, prediluted . . . . . . . . . . .380R-18 +1 520 .887 .2155 www.cellmarque.com
RUO
Positive control slides . . . . .380S or visit www.ventana.com
* Ventana and ultraView are trademarks of Roche. Cell Marque antibodies are developed, manufactured and distributed by Cell Marque Corporation and their sale through Ventana Medical Systems, Inc. does not imply
approval, endorsement, or any guarantee of quality or performance of those Cell Marque antibodies by Ventana.
Cadherin-17, also called liver-intestinal (LI) cadherin or human peptide transporter-1, is a member of the cadherin superfamily.
Unlike some classic cadherins, such as E-, N-, and P-cadherins, cadherin-17 has seven cadherin repeats instead of five within Reactivity Paraffin
the extracellular domain and only 20 amino-acid residues in the cytoplasmic domain. The markedly short cytoplasmic
domain lacks homology with other cadherins and the adhesive function of cadherin-17 is not dependent on association with Visualization Cytoplasmic,
other cytoplasmic proteins. The subcellular distribution of cadherin-17 is also different from classic cadherins. In intestinal Membranous
epithelial cells, E-cadherin is concentrated in adherens junctions whereas cadherin-17 is evenly distributed along the lateral
contact area. Human normal tissues that are strongly stained with cadherin-17 include appendicular epithelium, colonic Control Colorectal carcinoma
epithelium, and small intestinal epithelium. Other normal human tissues are not stained with cadherin-17. The results above Stability Up to 36 mo. at 2-8°C
indicate cadherin-17 can be used as a marker for identification of primary sites of tumors. In-house studies have shown
cadherin-17 expression is usually diffuse and strong in colorectal adenocarcinomas, whereas it is usually focal or scattered in Isotype IgG
adenocarcinomas of the stomach, pancreas and bile duct, and is virtually absent in tumors of other anatomic sites.
Protocols
Neoplasms • Pretreatment: EDTA/Trilogy
Cadherin-17 CDX-2 S100P GATA3 TTF-1 Napsin A
• Incubation Time:
Colorectal Adenocarcinoma + + - - - -
HiDef Detection™ 10-30 min. RT
Gastric Adenocarcinoma + + - - - -
or ultraView™ 16-32 min. at 37° C
Esophogeal Adenocarcinoma + + - - - -
Pancreatic Ductal Please refer to product insert for complete protocol.
-/+ +/- + - - -
Adenocarcinoma
Hepatocellular Carcinoma - - - - - -
Lung Adenocarcinoma - - - - + +
Breast Carcinoma - - - + - -
References
Ovarian Carcinoma - - - - - -
1. Su MC, et al. Mod Pathol. 2008;
21:1379–1386.
2. Gessner R, et al. Ann N Y Acad Sci.
2000; 915:136–143.
Rabbit Monoclonal
IVD
Clone: SP183
0.1 ml, concentrate .....................378R-14 IVD 1 800.665.7284 (N. America)
0.5 ml, concentrate .....................378R-15 +1 916.746.8900 (direct)
1 ml, concentrate ......................378R-16 IVD +1 916.746.8989 (fax)
1 ml, prediluted ........................378R-17 [email protected]
7 ml, prediluted ........................378R-18 www.cellmarque.com
RUO
Positive control slides ..................378S
* ultraView is a trademark of Roche.
Cell Marque New Product
Cathepsin K is a lysosomal papain-like cystine proteinase and can be expressed in normal osteoblasts, fibroblasts, and skin.
Recently, cathepsin K has been reported as useful in distinguishing translocation renal cell carcinoma (RCC) from other subtypes Reactivity Paraffin
of RCC. Mortignoni et al. tested 17 cases of translocation RCC and found that cathepsin K stained: 6 of 8 cases of translocation
RCC with t(X;1), all seven cases of translocation RCC with t(6;11), but was negative for one case with t(X;3) and one with t(X;17). Visualization Cytoplasmic
Additionally, the study compared IHC detection of TFE3 antibody in the 17 cases and demonstrated that all translocation
RCC with t(6;11) were completely negative for TFE3, but positive for cathepsin K; all other translocation RCC with different Control XP11.2 Translocation RCC
chromosomal tranlocations other than t(X;1) expressed TFE3. Thus, it is recommended that antibodies against both TFE3 and Stability Up to 36 mo. at 2-8°C
cathepsin K should be used for evaluating translocation renal cell carcinomas. None of the 305 other renal cell neoplasms
representing the most common renal cell neoplasm subtypes were positive for cathepsin K. Zheng et al. reported only 2.7% of Isotype IgG
1,140 carcinomas from various organs exhibited cathepsin K labeling, indicating that among carcinomas cathepsin K labeling 2b
is highly specific for translocation RCC and can be used to help differentiate translocation RCC from other carcinomas. Protocols
• Pretreatment: EDTA/Trilogy
Neoplasm • Incubation Time:
Cathepsin K TFE3 RCC CD117 CD34 GATA3
HiDef Detection™ 10-30 min. RT
XP11 translocation renal cell
+ + + -/+ - - or ultraView™ 16-32 min. at 37° C
carcinoma
Alveolar soft part sarcoma + - - - - - Please refer to product insert for complete protocol.
Rhabdomyosarcoma + - - - - -
Leiomyosarcoma + - - - - -
GIST + - - + + -
Melanoma + - - -/+ - - References
Renal cell carcinoma - - + +/- - -
Oncocytoma - - - +/- - -
1. Martignoni G, et al. Mod Pathol
Urothelial Carcinoma - - - - - + 2009;22:1016-22.
2. Zheng G, et al. Am J Clin Pathol
2013;139:151-9.
Mouse Monoclonal
IVD
Clone: 3F9
0.1 ml, concentrate .....................402M-14 IVD 1 800.665.7284 (N. America)
0.5 ml, concentrate .....................402M-15 +1 916.746.8900 (direct)
1 ml, concentrate ......................402M-16 IVD +1 916.746.8989 (fax)
1 ml, prediluted ........................402M-17 [email protected]
7 ml, prediluted ........................402M-18 www.cellmarque.com
RUO
Positive control slides ..................402S
* ultraView is a trademark of Roche.
Cell Marque New Product
Caveolin-1 (CAV-1) is a cell membrane-associated structural component of flask-shaped plasma membrane invaginations
termed caveolae. CAV-1 is expressed at different levels in different tissues, with the highest in adipocytes, endothelial cells, Reactivity Paraffin
fibroblasts, and mesothelial cells. Anti-CAV-1 is useful in assisting in the identification of epithelioid mesothelioma. A study
by Amatya et al. indicates CAV-1 expression in all 80 (100%) epithelioid mesotheliomas, whereas only 6/80 (7.5%) of the lung Visualization Membranous
adenocarcinomas were positive for CAV-1. Staining in most mesotheliomas was strong and diffuse when compared with
the weak, focal staining (no more than 1% of the tumor cells) seen in the lung adenocarcinomas, anti-CAV-1 is considered Control Ewing Sarcoma,
a very useful marker for assisting in discriminating between these two malignancies. They also indicated that anti-CAV-1 is Mesothelioma
comparable to other mesothelioma markers such as anti-calretinin and anti-D2-40 (podoplanin) that are commonly used Stability Up to 36 mo. at 2-8°C
to assist in the differentiation between epithelioid mesotheliomas and lung adenocarcinomas. Anti-CAV-1 is also useful in
identification of Ewing sarcoma/PNET. Literature indicates CAV-1 expression in 368 (96%) of 383 cases of Ewing sarcoma/ Isotype IgG
PNET. In summary, anti-CAV-1 is very useful in the differentiation of epithelioid mesothelioma from lung adenocarcinoma and 1
identification of Ewing sarcoma/PNET. Protocols
• Pretreatment: EDTA/Trilogy
Neoplasm • Incubation Time:
Thrombo-
HiDef Detection™ 10-30 min. RT
Caveolin-1 D2-40 modulin/ CK 5&6 WT1 Napsin A TTF-1 CEA Ber-EP4 MOC-31
Calretinin or ultraView™ 16-32 min. at 37° C
Epitheloid Mesothelioma + + + + + - - - - - Please refer to product insert for complete protocol.
Lung Adenocarcinoma - - - - - + + + + +
Lung Squamous Cell
+/- + - + - - - + +/- +
Carcinoma
Breast Invasive Ductal
Carcinoma - - - -/+ - - - + + + References
Renal Cell Carcinoma - - - - - + - - -/+ -/+
Ovarian Serous Carcinoma - + - +/- + - - + + + 1. Cohen AW, et al. Physiol Rev. 2004;
Hepatocellular Carcinoma - - - - - - - + -/+ - 84:1341-1379.
2. Amatya VJ, et al. Histopathology
2009; 55:10-19.
3. Llombart-Bosch A, et al. Virchows
Arch 2009; 455:397-411.
Mouse Monoclonal
IVD
Clone: 2297
0.1 ml, concentrate .....................412M-14 IVD 1 800.665.7284 (N. America)
0.5 ml, concentrate .....................412M-15 +1 916.746.8900 (direct)
1 ml, concentrate ......................412M-16 IVD +1 916.746.8989 (fax)
1 ml, prediluted ........................412M-17 [email protected]
7 ml, prediluted ........................412M-18 www.cellmarque.com
RUO
Positive control slides ..................412S
* ultraView is a trademark of Roche.
Cell Marque New Product
CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can
be found in the bone marrow. Anti-CD2 is a pan-T-cell antigen marker. Anti-CD2 is therefore useful for the identification of Reactivity Paraffin
virtually all normal T-lymphocytes. It is also very useful in the assessment of lymphoid malignancies as it is expressed in the
majority of precursor and mature T-cell lymphomas and leukemias. As with other pan-T-cell antigens, CD2 may be aberrantly Visualization Cytoplasmic,
deleted in some neoplastic T-cell populations, especially peripheral T-cell lymphomas. When combined with anti-CD25, anti- Membranous
CD2 may assist in the identification of systemic mastocytosis and mastocytic leukemia.
Control Tonsil
T-cell Lymphomas Stability Up to 36 mo . at 2-8°C
CD2 CD45 CD3 CD4 CD5 CD7 CD8 CD25 CD45RO PD-1
Angioimmunoblastic + + + + + + - + + + Isotype EP222: IgG
Lymphoblastic +/- + + +/- + + +/- + + -
MRQ-11: IgG/k
Subcutaneous 1
+ + + - + + +/- - + -
Panniculitis-Like
Protocols
NK + + + - - -/+ - + + -
Cutaneous + + + + - + - - - -/+ • Pretreatment: EDTA/Trilogy™
Peripheral, NOS + + + +/- +/- +/- -/+ + + -
• Incubation Time:
Mycosis Fungoides + + + + + - - + + -
HiDef Detection™ 10-30 min . RT
or ultraView™ 16-32 min . at 37° C
Mastocytosis
Please refer to product insert for complete protocol.
CD2 Tryptase CD117 CD25 CD163
Mastocytosis + + + + -
Mastocytic Leukemia + + + + -
Reactive Mast Cells - + + - +
References
1 . Aguilera NS, et al . Arch Pathol Lab
Med . 2006; 130:1772-9 .
2 . Barrionuevo C, et al . Appl
Immunohistochem Mol Morphol .
2007; 15:38-44 .
Mouse Monoclonal Mouse Monoclonal Rabbit Monoclonal
IVD
Clone: MRQ-11 Clone: MRQ-11 Clone: EP222
0 .1 ml, concentrate . . . . . . . .102M-14 Ventana® 50 Test Dispenser IVD 0 .1 ml, concentrate . . . . . . . .102R-14 1 800.665.7284 (N. America)
0 .5 ml, concentrate . . . . . . . .102M-15 760-4377 0 .5 ml, concentrate . . . . . . . .102R-15 +1 916.746.8900 (direct)
1 ml, concentrate . . . . . . . . .102M-16 IVD 1 ml, concentrate . . . . . . . . .102R-16 +1 916.746.8989 (fax)
Dispenser orders:
1 ml, prediluted . . . . . . . . . . .102M-17 1 ml, prediluted . . . . . . . . . . .102R-17 [email protected]
1 800 .227 .2155
7 ml, prediluted . . . . . . . . . . .102M-18 +1 520 .887 .2155 7 ml, prediluted . . . . . . . . . . .102R-18 www.cellmarque.com
RUO
Positive control slides . . . . .102S or visit www.ventana.com Positive control slides . . . . .102S
* Ventana and ultraView are trademarks of Roche. Cell Marque antibodies are developed, manufactured and distributed by Cell Marque Corporation and their sale through Ventana Medical Systems, Inc. does not imply
approval, endorsement, or any guarantee of quality or performance of those Cell Marque antibodies by Ventana.
CD4 is a 55 kD glycoprotein expressed on the surface of T-helper/regulatory T-cells, monocytes, macrophages, and dendritic
cells. Anti-CD4 is used in the immunophenotyping of lymphoproliferative disorders. The majority of peripheral T-cell Reactivity Paraffin
lymphomas are derived from the T-helper/regulatory cell subset so that most mature T-cell neoplasms are CD4+ CD8-. As with
other T-cell antigens, CD4 may be aberrantly expressed in neoplastic T-cells so that the evaluation of such tumors requires the Visualization Cytoplasmic,
application of a panel of markers in order to identify tumors with CD4 aberrant expression. Membranous
Control Tonsil, Lymph Node
T-cell Lymphomas
CD4 CD45 CD2 CD3 CD5 CD7 CD8 CD25 CD45RO PD-1 Stability Up to 36 mo. at 2-8°C
Angioimmunoblastic + + + + + + - + + +
Lymphoblastic +/- + +/- + + + +/- + + - Isotype EP204: IgG
Subcutaneous
Panniculitis-Like - + + + + + +/- - + - SP35: IgG
NK - + + + - -/+ - + + -
Protocols
Cutaneous + + + + - + - - - -/+
Peripheral, NOS +/- + + + +/- +/- -/+ + + -
• Pretreatment: EDTA/Trilogy
Mycosis Fungoides + + + + + - - + + -
• Incubation Time:
HiDef Detection™ 10-30 min. RT
Histiocytic Neoplasms
or ultraView™ 16-32 min. at 37° C
CD4 CD45 CD68 Lysozyme CD163 Factor XIIIa CD20 CD3
Histiocytic Neoplasms + + + + + + - - Please refer to product insert for complete protocol.
References
1. Leong AS-Y, et al. Manual of
diagnostic antibodies for immuno-
histochemistry, 2nd edition 2003;
Greenwich Medical Media Ltd.
2. Akiyama T, et al. Pathol Int. 2008
Oct;58(10):626-34.
Rabbit Monoclonal Rabbit Monoclonal
N E W! IVD
Clone: EP204 Clone: SP35
0.1 ml, concentrate .....................104R-24 IVD 0.1 ml, concentrate .....................104R-14
0.5 ml, concentrate .....................104R-25 0.5 ml, concentrate .....................104R-15 1 800.665.7284 (N. America)
1 ml, concentrate ......................104R-26 IVD 1 ml, concentrate ......................104R-16 +1 916.746.8900 (direct)
1 ml, prediluted ........................104R-27 1 ml, prediluted ........................104R-17 +1 916.746.8989 (fax)
7 ml, prediluted ........................104R-28 7 ml, prediluted ........................104R-18 [email protected]
RUO
Positive control slides ..................104S Positive control slides ..................104S www.cellmarque.com